TY - JOUR
T1 - Colorectal cancer screening by detection of altered human DNA in stool
T2 - Feasibility of a multitarget assay panel
AU - Ahlquist, David A.
AU - Skoletsky, Joel E.
AU - Boynton, Kevin A.
AU - Harrington, Jonathan J.
AU - Mahoney, Douglas W.
AU - Pierceall, William E.
AU - Thibodeau, Stephen N.
AU - Shuber, Anthony P.
N1 - Funding Information:
Supported by grants from the National Cancer Institute of National Institutes of Health (R01 CA 7160), EXACT Laboratories (Maynard, MA), and Mayo Foundation (Rochester, MN) and by the philanthropic support of Charles W. Oswald.
PY - 2000
Y1 - 2000
N2 - Background & Aims: Assay of altered DNA exfoliated into stool represents an Intriguing approach to screen for colorectal neoplasia, but multiple markers must be targeted because of genetic heterogeneity. We explored the feasibility of a stool assay panel of selected DNA alterations in discriminating subjects with colorectal neoplasia from those without. Methods: Freezer-archived stools were analyzed in blinded fashion from 22 patients with colorectal cancer, 11 with adenomas 5:1 cm, and 28 with endoscopically normal colons. After isolation of human DNA from stool by sequence-specific hybrid capture, assay targets included point mutations at any of 15 sites on K-ras, p53, and APC genes; Bat-26, a microsatellite instability marker; and highly amplifiable DNA. Results: Analyzable human DNA was recovered from all stools. Sensitivity was 91% (95% confidence interval, 71%-99%) for cancer and 82% (48%98%) for adenomas 2:1 cm with a specificity of 93% (76%-99%). Excluding K-ras from the panel, sensitivities for cancer were unchanged but decreased slightly for adenomas to 73% (39%-94%), while specificity increased to 100% (88%-100%). Conclusions: Assay of altered DNA holds promise as a stool screening approach for colorectal neoplasia. Larger clinical investigations are indicated.
AB - Background & Aims: Assay of altered DNA exfoliated into stool represents an Intriguing approach to screen for colorectal neoplasia, but multiple markers must be targeted because of genetic heterogeneity. We explored the feasibility of a stool assay panel of selected DNA alterations in discriminating subjects with colorectal neoplasia from those without. Methods: Freezer-archived stools were analyzed in blinded fashion from 22 patients with colorectal cancer, 11 with adenomas 5:1 cm, and 28 with endoscopically normal colons. After isolation of human DNA from stool by sequence-specific hybrid capture, assay targets included point mutations at any of 15 sites on K-ras, p53, and APC genes; Bat-26, a microsatellite instability marker; and highly amplifiable DNA. Results: Analyzable human DNA was recovered from all stools. Sensitivity was 91% (95% confidence interval, 71%-99%) for cancer and 82% (48%98%) for adenomas 2:1 cm with a specificity of 93% (76%-99%). Excluding K-ras from the panel, sensitivities for cancer were unchanged but decreased slightly for adenomas to 73% (39%-94%), while specificity increased to 100% (88%-100%). Conclusions: Assay of altered DNA holds promise as a stool screening approach for colorectal neoplasia. Larger clinical investigations are indicated.
UR - http://www.scopus.com/inward/record.url?scp=0034322371&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034322371&partnerID=8YFLogxK
U2 - 10.1053/gast.2000.19580
DO - 10.1053/gast.2000.19580
M3 - Article
C2 - 11054379
AN - SCOPUS:0034322371
SN - 0016-5085
VL - 119
SP - 1219
EP - 1227
JO - Gastroenterology
JF - Gastroenterology
IS - 5
M1 - 89526
ER -